Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)

Organism: Homo sapiens, human  / 

Organism Homo sapiens, human
Components
HCC2157, ATCC CRL-2340
HCC1599, ATCC CRL-2331
HCC1937, ATCC CRL-2336
HCC1599, ATCC CRL-2321
MDA-MB-468, ATCC HTB-132
HCC38, ATCC CRL-2314
HCC70, ATCC CRL-2315
HCC1806, ATCC CRL-2335
HCC1187, ATCC CRL-2322
DU4475, ATCC HTB-123
BT-549, ATCC HTB-122
Hs 578T, ATCC HTB-126
MDA-MB-231, ATCC HTB-26
MDA-MB-436, ATCC HTB-130
MDA-MB-157, ATCC HTB-24
MDA-MB-453, ATCC HTB-131
BT-20, ATCC HTB-19
HCC1395, ATCC CRL-2324
Applications
Biological understanding of top genetic alterations across tumor types
Validation and characterization of potential cancer driver genes
Functional profiling and molecular profiling of subtype-specific cancer cell lines
Testing small molecules or biologics for cancer drug development
Type Strain no
Biosafety Level 1
Comments
A panel of 18 triple-negative breast tumor cell lines sharing a mesenchymal-like or luminal morphology. See J Clinical Inv (2011) 121(7):2750-2767 for more information.
RefLehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121: 2750-2767, 2011. PubMed: 21633166
Product Format frozen
Storage Conditions LN vapor (less than -130°C) only